GenomeDx Biosciences and Astellas announced a collaboration to apply genomic tumor profiling using GenomeDx’s Decipher Classifier and Decipher GRID as a potential aid in identifying prostate cancer patients undergoing active surveillance who may benefit from treatment with enzalutamide (Xtandi).
How’s this for a paradox: The better cancer centers become at keeping patients alive, the more expensive cancer care becomes. This brutal tradeoff hits harder in rural areas, where the cancer burden is higher and the investigator and clinical trial representation is lower.
